comparemela.com

Latest Breaking News On - Bio media contact - Page 11 : comparemela.com

BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers

/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced.

New-york
United-states
Columbia-university
Bio-pharma
Orin-herskowitz
Neil-kumar
Katherine-yau
Linkedin
Twitter
National-institute-for
Nasdaq
Columbia-technology-ventures

BridgeBio : Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has. | October 25, 2021

Stanford-university
California
United-states
Stanford
Neil-kumar
Pacific-biosciences
Hannah-valantine
Katherine-yau
National-institutes-of-health
Stanford-university-school-of-medicine
Nasdaq
National-academy-of-medicine

BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced.

Stanford-university
California
United-states
Stanford
Neil-kumar
Pacific-biosciences
Hannah-valantine
Katherine-yau
National-institutes-of-health
Stanford-university-school-of-medicine
Nasdaq
National-academy-of-medicine

BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced.

Stanford-university
California
United-states
Stanford
Neil-kumar
Pacific-biosciences
Hannah-valantine
Katherine-yau
National-institutes-of-health
Stanford-university-school-of-medicine
Nasdaq
National-academy-of-medicine

BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers

/PRNewswire/ BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, is announcing.

United-states
American
Charles-homcy
Bridgebio-bio
Bridgebio-cardiorenal
Katherine-yau
Eli-wallace
Mary-scott-roberts
Richard-scheller
Neil-kumar
Jonathan-fox
Suma-sinha

vimarsana © 2020. All Rights Reserved.